HMNC completes subject randomisation in Phase IIb MDD treatment trial
HMNC Brain Health (HMNC) has completed the subject randomisation in its placebo-controlled Phase IIb OLIVE trial of a vasopressin V1b…
Central Nervous System
-
-
Alzheimer’s disease market expected to reach $19.3bn across the 8MM by 2033
The Alzheimer’s disease market is expected to grow at a high compound annual growth rate (CAGR) of 23.4% from $2.4bn…
-
Contineum concludes enrolment in Phase II multiple sclerosis therapy trial
Contineum Therapeutics has concluded the targeted enrolment of 168 subjects in its Phase II trial of M1 receptor antagonist PIPE-307…
-
BIAL’s first subject completes full dose regimen in Parkinson’s treatment trial
BIAL has reported the completion of the full dose regimen for the first subject in the multicentre Phase II ACTIVATE…
-
IMCA renews SciSparc’s autism spectrum disorder therapy trial approval
Israeli Medical Cannabis Agency (IMCA) at the Ministry of Health has renewed SciSparc’s clinical trial of SCI-210 aimed at treating…
-
Alumis reports positive outcomes from Phase I trial of TYK2 inhibitor
Alumis has revealed encouraging results from a Phase I clinical trial of a selective tyrosine kinase 2 (TYK2) inhibitor, A-005,…
-
MindMed doses first subject in trial of tablets for generalised anxiety disorder
US-based biotechnology company Mind Medicine (MindMed) has dosed the first subject in the 52-week Phase III Voyage study of MM120…
-
AbbVie’s Phase III trial of Parkinson’s disease treatment meets primary endpoint
US-based pharmaceutical company AbbVie has reported that the Phase III TEMPO-2 trial of tavapadon, its D1/D5 partial agonist candidate for…
-
BioArctic doses first subject in Parkinson’s disease therapy trial
BioArctic has dosed the first subject with the monoclonal antibody, exidavnemab, in the randomised Phase IIa EXIdavnemab Synucleinopathy Trial (EXIST)…
-
Nuvig secures $161m financing to support clinical studies for NVG-2089
Nuvig Therapeutics has closed a $161m Series B financing round to advance its preclinical pipeline and support NVG-2089’s clinical proof-of-concept…
